A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Effects of BMS-823778 on Atherosclerotic Plaque Inflammation as Measured by Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET) in Patients With Atherosclerotic Cardiovascular Disease
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2013
At a glance
- Drugs BMS 823778 (Primary)
- Indications Atherosclerosis; Cardiovascular disorders
- Focus Therapeutic Use
- 19 Jun 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 28 Mar 2013 Planned End Date changed from 1 Nov 2015 to 1 May 2016 as reported by ClinicalTrials.gov.
- 14 Mar 2013 Planned initiation date changed from 1 Aug 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov.